|
KMID : 1035520220100020101
|
|
Brain Tumor Research and Treatment : BTRT
2022 Volume.10 No. 2 p.101 ~ p.107
|
|
|
Recent Update in Pharmacological Agents for Optic Pathway Glioma
|
|
Park Mee-Rim
|
|
|
Abstract
|
|
|
|
Optic pathway gliomas (OPGs) are insidious, debilitating low-grade tumors. They can affect the optic nerve, optic chiasm, and optic tracts and can be sporadic or associated with neurofibromatosis type 1 (NF1). The location of OPGs within the optic pathway typically precludes complete resection or optimal radiation dose. Treatment is unnecessary for sporadic and NF1-related OPGs that do not cause visual impairments. Chemotherapy is the mainstay of treatment for patients with progressive disease. How- ever, outcomes following standard treatments have been mixed, and standardized outcome measure- ments are lacking. In recent years, newer molecularly targeted therapies such as anti-vascular endo- thelial growth factor (VEGF) monoclonal antibody, mitogen-activated protein kinase (MAPK) inhibitor, and mammalian target of rapamycin (mTOR) inhibitor, represent a promising treatment modality.
|
|
|
KEYWORD
|
|
|
Optic pathway glioma, Chemotherapy, Anti-VEGF antibody, MAPK inhibitor, mTOR inhibitor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|